Fifty 1 Labs, Inc. is a Nevada-based holding company focused on health, wellness, and biotech through AI-driven drug repurposing and functional medicine. The Company operates subsidiaries including Fifty1 AI Labs LLC and 51 Labs LLC, which focus on personalized medicine, sports nutrition, and advanced therapeutics. Fifty1 AI Labs LLC delivers transformative solutions for patients and shareholders. 51 Labs LLC offers a line of supplements including pre-workout formulas, BCAAs, ION+ Electrolyte Formula, Turmeric Gummies, and Ashwagandha Gummies designed to enhance athletic performance, recovery, and overall health.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-17	0.000100 $	0.00%	4,000

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets Other stock markets 09:30:19 2026-06-17 EDT			5-day change	1st Jan Change
0.000100 ^USD	0.00%		0.00%	-

01-05	Fifty 1 Labs, Inc. Announces CEO Changes	CI
25-08-14	Fifty 1 Labs, Inc. Announces the Completion of the Largest and Most Comprehensive Study of Sickle Cell Disease	CI

Market Cap	281K 245K 227K 213K 399K 26.56M 401K 2.7M 1.05M 13.07M 1.06M 1.03M 45.4M	P/E 2009	-0.05x	P/E 2010	-0.01x
Enterprise Value	12.55M 10.95M 10.14M 9.49M 17.8M 1.18B 17.91M 120M 46.61M 583M 47.13M 46.12M 2.02B	EV / Sales 2009	1.86x	EV / Sales 2010	2.41x
Free-Float	57.9%	Yield 2009 *	-	Yield 2010	-

01-05	Fifty 1 Labs, Inc. Announces CEO Changes	CI
25-08-14	Fifty 1 Labs, Inc. Announces the Completion of the Largest and Most Comprehensive Study of Sickle Cell Disease	CI
25-07-10	Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling 50 1 Labs, Inc. Toward $50 Million Valuation	CI
25-04-30	Fifty 1 Labs, Inc. Appoints Michael Lawson as Chairman of the Board	CI
25-04-30	Fifty 1 Labs, Inc. Appoints Michael Lawson as Chief Executive Officer	CI
25-04-30	The Fifty 1 Labs Biosentry Division Will Develop State-Of-The-Art Biohazard Sensing Sensors Capable of Detecting Pathogens	CI
25-04-30	UAV Corp. Announces Strategic Partnership with 50 1 Labs, Inc	CI
25-04-08	Uav Corp And Genetic Networks Announce Strategic Collaboration	RE
25-03-20	Fifty 1 Labs, Inc. Appoints Gennaro D'Urso as CEO	CI
25-03-20	Fifty 1 Labs, Inc. Appoints Gennaro D'urso as Chairman	CI
25-03-19	Fifty 1 Labs, Inc. acquired Genetic Networks, LLC for $0.02 million.	CI
25-03-14	Consumer Automotive Finance, Inc has Changed its Name to Fifty 1 Labs, Inc	CI
25-03-14	Fifty 1 Labs, Inc. has Changed its Ticker to FITY from CAFI	CI

04-15	Fifty 1 Labs, Inc. Accelerates Peptide Biotechnology Push into Musculoskeletal Health	AQ
04-14	Fifty 1 Labs, Inc. Eliminates 612 Million Shares from the Market	AQ
01-05	Fifty1 Labs, Inc. Clarifies Status Regarding Previously Announced Collaboration with LUNR Aerospace	AQ
25-10-09	Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer	AQ
25-09-30	Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc.	AQ

Fifty 1 Labs, Inc. Stock OTC Markets

Stocks

NWAU

US67012P1093

Biotechnology & Medical Research

Valuation: Fifty 1 Labs, Inc.

Chart: Fifty 1 Labs, Inc.

Latest news : Fifty 1 Labs, Inc.

Press Releases: Fifty 1 Labs, Inc.

Course Extremes

Managers and Directors: Fifty 1 Labs, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0.02
5 years	0		0.04
10 years	0		0.4

Manager	Title	Age	Since
Pritpaul Singh Arora CEO	Chief Executive Officer	47	-
Brandon Spikes PSD	President	-	-
Alind Gupta CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Robert Clark BRD	Director/Board Member	49	2025-04-29
Brandon Spikes CHM	Chairman	-	2023-07-11
Curtis Young BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FIFTY 1 LABS, INC.	0.00%	0.00%	-	-	711K
LONZA GROUP AG	+1.44%	+1.71%	-10.98%	-6.19%	43.13B
REVOLUTION MEDICINES, INC.	+3.31%	+5.93%	+310.97%	+534.70%	34.65B
BEONE MEDICINES AG	+2.84%	+2.14%	+9.34%	+41.02%	30.03B
IQVIA HOLDINGS INC.	-1.70%	-7.54%	+8.43%	-21.94%	28B
CELLTRION, INC.	-1.90%	-1.56%	+10.24%	+21.21%	24.45B
ASCENDIS PHARMA A/S	-0.14%	+5.86%	-	-	14.34B
MEDPACE HOLDINGS, INC.	+0.68%	-1.53%	+48.76%	+104.27%	13.14B
EUROFINS SCIENTIFIC SE	-0.57%	-2.43%	+5.08%	+4.79%	12.53B
IONIS PHARMACEUTICALS, INC.	-0.26%	+1.15%	+98.13%	+80.47%	12.25B
Average	+0.37%	+0.73%	+60.00%	+94.79%	23.61B
Weighted average by Cap.	+0.77%	+1.27%	+65.47%	+110.06%

	2009	2010
Net sales	5.41M 4.72M 4.37M 4.09M 7.67M 511M 7.72M 51.84M 20.09M 251M 20.31M 19.88M 873M	5.11M 4.45M 4.12M 3.86M 7.24M 482M 7.28M 48.92M 18.96M 237M 19.17M 18.76M 824M
Net income	-2.23M -1.95M -1.8M -1.69M -3.16M -211M -3.18M -21.38M -8.29M -104M -8.38M -8.2M -360M	-1.89M -1.65M -1.53M -1.43M -2.69M -179M -2.7M -18.15M -7.03M -87.98M -7.11M -6.96M -305M
Net Debt	9.96M 8.68M 8.04M 7.53M 14.11M 939M 14.2M 95.37M 36.96M 462M 37.37M 36.57M 1.61B	12.27M 10.7M 9.91M 9.28M 17.4M 1.16B 17.51M 118M 45.57M 570M 46.07M 45.08M 1.98B